Levosimendan in decompensated heart failure patients: Efficacy in a Brazilian cohort. Results of the BELIEF study;Levosimendana em pacientes com insuficiência cardíaca descompensada: Eficácia em uma coorte Brasileira. Resultados do estudo BELIEF

Arquivos Brasileiros de Cardiologia

Volumn 90, Issue 3, 2008, Pages

  Bocchi, Edimar Alcides ^a,h   Vilas Boas, Fábio ^b   Moreira, Maria Da Consolação ^c   Barretto, Antonio Carlos Pereira ^a   Lage, Silvia ^a   Albuquerque, Denilson ^d   Baima, Jader ^e   Rassi, Salvador ^f   Ribeiro, Jorge Pinto ^g  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL SANTA IZABEL   (Brazil)

^c HOSPITAL FELÍCIO ROCHO   (Brazil)

^d HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^e Departamento de Pesquisas Clínicas Dos Laboratórios Abbott   (Brazil)

^f Hospital Das Clínicas da UFG

^g Hospital Das Clinicas da UFRS

^h Rua Oscar Freire   (Brazil)

Author keywords

Chagas disease; Decompensated congestive heart failure; Decompensated heart failure; Dyspnea; Heart failure; Inotropic drug; Levosimendan; Systolic blood pressure

Indexed keywords

AMINOPHYLLINE; AMIODARONE; ANGIOTENSIN II ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENALAPRIL; ENOXAPARIN; FUROSEMIDE; HEPARIN; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; LANATOSIDE C; LEVOSIMENDAN; LOSARTAN; METOPROLOL; NITROPRUSSIDE SODIUM; NORADRENALIN; POTASSIUM CHLORIDE; RAMIPRIL; UNINDEXED DRUG; VALSARTAN;

ADULT; AGED; ARTICLE; BRAZIL; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HEART FAILURE; HEART HEMODYNAMICS; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 42049110985     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2008000300008     Document Type: Article

References (40)

1. Bocchi EA, Vilas-Boas F, Perrone S, Caamaño AG, Clausell N, Moreira MC, et al for I Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure. Group. I Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure. Arq Bras Cardiol. 2005; 85 (supl 3):49-94; 1-48.
2. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005; 293: 1900-5.
3. Lehtonen LA. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Exp Opin Invest Drugs. 2001; 10: 955-70.
4. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000; 102: 2222-7.
5. Hasenfuss G, Pieske B, Catell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in falling human myocardium. Circulation. 1998; 98: 2141-7.
6. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan a novel Ca++ sensitizer activates the glibenclamide-sensitive K+ channels in rat arterial myocytes. Eur J Pharmacol. 1997; 333: 249-59.
7. Follath F, Cleland JGF, Just H, Papp JG, Scholz H, Peurkurinen K, et al. Efficacy and safety of intravenous levosimendan, a novel calcium sensitiser, in severe low output failure. Lancet. 2002; 360: 196-202.
8. Moiseyev VS, Poder P, Andrejevs N on behalf of RUSSLAN investigators: Randomized study on safety and effectiveness of levosimendan in patients with left ventricular heart failure after an acute myocardial infarction (the RUSSLAN study). Eur Heart J. 2002: 23: 1422-32.
9. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. and SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297: 1883-91.
10. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006; 8 (1): 105-10.
11. Levosimendan does not aid HF survival (on line). [acesso em 2007 mai 18]. Disponível em http://www.cvspectrum.org/cms/templates/article.aspx?
12. Rector TS, Kubo SH, Cohn JN. Patients'self-assessment of their congestive heart failure. Heart Fail. 1987; 1: 192-209.
13. Nieminen M, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Haemodynamic and neurohormonal effects of continuous infusion of levosimedan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36: 1903-12.
14. Janssen PML, Datz N, Zeitz O, Hasenfuss G. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmocol. 2000; 404: 191-9.
15. Pagel OS, McGough MF, Hettrick DA, Lowe D, Tessmer JP, Jamali IN, et al. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol. 1997; 29: 563-73.
16. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac tropinin-C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995; 27: 1859-66.
17. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther. 1997; 283: 375-83.
18. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1999; 288: 316-35.
19. Lochner A, Colesky F, Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium. Cardiovasc Drugs Ther. 2000; 14: 271-81.
20. Ajiro Y, Hagiwara N, Katsube Y, Sperelakis N, Kasanuki H. Levosimendan increases L-type Ca(2+) current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol. 2002; 435: 27-33.
21. Pagel PS, Hettrick DA, Warltier DC. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol. 1996; 91: 296-307.
22. Kersten JR, Montgomery MW, Pagel OS, Warltier DC. Levosimendan: a new positive inotropic drug decreases myocardial intarct size via activation of K-ATP channels. Anesth Analg. 2000; 90: 5-11.
23. Ukkonen H, Knuuti J, Ruskoaho H, Noakes T, Lehikoinen P. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000; 68: 522-31.
24. Nicklas JM, Monsur JC, Bleske BE. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol. 1999; 83 (12 B): 12-5.
25. Lehtonen L. Levosimendan: a promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Rep. 2000; 2: 223-43.
26. Dernellis J, Panaretou M. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study. Chest. 2005; 128: 2633-9.
27. Bristow MR, Linas S, Port JD. Drugs in the treatment of heart failure. In: Zipes DP, Braunwald E, Libby P, Bonow RO. Braunwald's heart disease: a textbook of cardiovascular medicine. 7th ed. Phyladelphia: Elsevier Saunders; 2005. p. 569-601.
28. MacGowan GA. What is the in vivo mechanism of action of levosimendan. Letter . J Card Fail. 2005; 11: 482-3.
29. Bodi A, Szilagyi S, Edes I, Papp Z. The cardiotonic effects of levosiemdan in ginea pig hearts are modulated by beta-adrenergic stimulation. Gen Physiol Biophys. 2003; 22: 313-27.
30. Mebazaa A, Barraud D, Welschbillig S. Randomized clinical trials with levosimendan Am J Cardiol. 2005; 96: 74G-79G.
31. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure. JAMA. 2003; 290: 2581-7.
32. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003; 41: 1797-804.
33. Wolff MR, Buck SH, Stoker SW, Greaser ML, Mentzer RM. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies. J Clin Invest. 1996;98:167-76.
34. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, Zeew D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000; 102: 203-10.
35. Follath F, Franco F, Cardoso JS. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol. 2005; 96 (6 A): 80G-5G.
36. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999; 138: 285-90.
37. Wilkberg T, Salonen J, Lautala P. Metabolite profiles of intravenous 14 C-levosimendan in urine and faeces. Orion Pharma: Internal report number PRE9911032, April 28, 2000.
38. Rector TS. Overview of the Minnesota living with heart failure questionnaire. [acesso em 2005 Nov 2]. Disponível em http://www.mlhfq. org/_dnld/mlhfq_overview.doc.
39. Babayan ZV, McNamara RL, Nagajothi N, Kasper EK, Armenian HK, Powe NR, et al. Predictors of cause-specific hospital readmissions in patients with heart failure. Clin Cardiol. 2003; 26: 411-8.
40. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacodynamci and safety of a new calcium sensitizer, levosimendan, and its metabolites during and extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002; 42: 43-51.